Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 17/20 | 0.72 |
| ▸ | TEK | Q02763 | 14/20 | 0.72 |
| ▸ | KDR | P35968 | 12/20 | 0.72 |
| ▸ | JAK3 | P52333 | 2/20 | 0.72 |
| ▸ | JAK2 | O60674 | 1/20 | 0.72 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.72 |
| ▸ | INSR | P06213 | 1/20 | 0.72 |
| ▸ | FES | P07332 | 1/20 | 0.72 |
| ▸ | LYN | P07948 | 1/20 | 0.72 |
| ▸ | FGR | P09769 | 1/20 | 0.72 |
| ▸ | KIT | P10721 | 1/20 | 0.72 |
| ▸ | JAK1 | P23458 | 1/20 | 0.72 |
| ▸ | CSK | P41240 | 1/20 | 0.72 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496131 | 0.96 | LCK (0.71) | LCKTEKKDRJAK3JAK2 | |
| SCHEMBL13220187 | 0.91 | TEK (0.80) | LCKTEKKDRJAK3JAK2 | |
| SCHEMBL13219938 | 0.91 | TEK (0.80) | LCKTEKKDRJAK3JAK2 | |
| SCHEMBL13220026 | 0.89 | TEK (0.72) | LCKTEKKDRJAK3JAK2 | |
| SCHEMBL5496870 | 0.88 | LCK (0.68) | LCKTEKKDRJAK3JAK2 | |
| SCHEMBL14568238 | 0.87 | LCK (0.61) | LCKTEKKDRJAK3JAK2 | |
| SCHEMBL5498521 | 0.87 | LCK (0.61) | LCKTEKKDRJAK3JAK2 | |
| SCHEMBL13219946 | 0.87 | KDR (0.79) | LCKTEKKDRJAK3JAK2 | |
| SCHEMBL13219739 | 0.87 | KDR (0.79) | LCKTEKKDRJAK3JAK2 | |
| SCHEMBL5496630 | 0.85 | LCK (0.67) | LCKTEKKDRJAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | claimed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | claimed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | claimed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | claimed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | LCK 106/4885TEK 836/4885KDR 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.